A proteomics panel for predicting optimal primary cytoreduction in stage III/IV ovarian cancer

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

A proteomics panel for predicting optimal primary cytoreduction in stage III/IV ovarian cancer. / Risum, Signe; Høgdall, Estrid; Engelholm, Svend A; Fung, Eric; Lomas, Lee; Yip, Christine; Petri, Anette L; Nedergaard, Lotte; Lundvall, Lene; Høgdall, Claus; Risum, Signe; Høgdall, Estrid; Engelholm, Svend A; Fung, Eric; Lomas, Lee; Yip, Christine; Petri, Anette L; Nedergaard, Lotte; Lundvall, Lene; Høgdall, Claus.

I: International Journal of Gynecological Cancer, Bind 19, Nr. 9, 01.12.2009, s. 1535-8.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Risum, S, Høgdall, E, Engelholm, SA, Fung, E, Lomas, L, Yip, C, Petri, AL, Nedergaard, L, Lundvall, L, Høgdall, C, Risum, S, Høgdall, E, Engelholm, SA, Fung, E, Lomas, L, Yip, C, Petri, AL, Nedergaard, L, Lundvall, L & Høgdall, C 2009, 'A proteomics panel for predicting optimal primary cytoreduction in stage III/IV ovarian cancer', International Journal of Gynecological Cancer, bind 19, nr. 9, s. 1535-8. https://doi.org/10.1111/IGC.0b013e3181a840f5, https://doi.org/10.1111/IGC.0b013e3181a840f5

APA

Risum, S., Høgdall, E., Engelholm, S. A., Fung, E., Lomas, L., Yip, C., Petri, A. L., Nedergaard, L., Lundvall, L., Høgdall, C., Risum, S., Høgdall, E., Engelholm, S. A., Fung, E., Lomas, L., Yip, C., Petri, A. L., Nedergaard, L., Lundvall, L., & Høgdall, C. (2009). A proteomics panel for predicting optimal primary cytoreduction in stage III/IV ovarian cancer. International Journal of Gynecological Cancer, 19(9), 1535-8. https://doi.org/10.1111/IGC.0b013e3181a840f5, https://doi.org/10.1111/IGC.0b013e3181a840f5

Vancouver

Risum S, Høgdall E, Engelholm SA, Fung E, Lomas L, Yip C o.a. A proteomics panel for predicting optimal primary cytoreduction in stage III/IV ovarian cancer. International Journal of Gynecological Cancer. 2009 dec. 1;19(9):1535-8. https://doi.org/10.1111/IGC.0b013e3181a840f5, https://doi.org/10.1111/IGC.0b013e3181a840f5

Author

Risum, Signe ; Høgdall, Estrid ; Engelholm, Svend A ; Fung, Eric ; Lomas, Lee ; Yip, Christine ; Petri, Anette L ; Nedergaard, Lotte ; Lundvall, Lene ; Høgdall, Claus ; Risum, Signe ; Høgdall, Estrid ; Engelholm, Svend A ; Fung, Eric ; Lomas, Lee ; Yip, Christine ; Petri, Anette L ; Nedergaard, Lotte ; Lundvall, Lene ; Høgdall, Claus. / A proteomics panel for predicting optimal primary cytoreduction in stage III/IV ovarian cancer. I: International Journal of Gynecological Cancer. 2009 ; Bind 19, Nr. 9. s. 1535-8.

Bibtex

@article{85990640836811df928f000ea68e967b,
title = "A proteomics panel for predicting optimal primary cytoreduction in stage III/IV ovarian cancer",
abstract = "The objective of this prospective study was to evaluate CA-125 and a 7-marker panel as predictors of incomplete primary cytoreduction in patients with stage III/IV ovarian cancer (OC). From September 2004 to January 2008, serum from 201 patients referred to surgery for a pelvic tumor was analyzed for CA-125. In addition, serum was analyzed for 7 biomarkers using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. These biomarkers were combined into a single-valued ovarian-cancer-risk index (OvaRI). CA-125 and OvaRI were evaluated as predictors of cytoreduction in 75 stage III/IV patients using receiver operating characteristic curves. Complete primary cytoreduction (no macroscopic residual disease) was achieved in 31% (23/75) of the patients. The area under the receiver operating characteristic curve was 0.66 for CA-125 and 0.75 for OvaRI. The sensitivity and specificity of CA-125 for predicting incomplete cytoreduction were 71% (37/52) and 57% (13/23), respectively (P = 0.04). The sensitivity and specificity of OvaRI for predicting incomplete cytoreduction were 73% (38/52) and 70% (16/23), respectively (P = 0.001). In conclusion, CA-125 and an index of 7 biomarkers were found to be predictors of cytoreduction. However, future studies of biomarkers are anticipated to promote early diagnosis and provide prognostic information to guide treatment of OC patients. In addition, new biomarkers might also play a role in predicting outcome from primary surgery in OC patients.",
author = "Signe Risum and Estrid H{\o}gdall and Engelholm, {Svend A} and Eric Fung and Lee Lomas and Christine Yip and Petri, {Anette L} and Lotte Nedergaard and Lene Lundvall and Claus H{\o}gdall and Signe Risum and Estrid H{\o}gdall and Engelholm, {Svend A} and Eric Fung and Lee Lomas and Christine Yip and Petri, {Anette L} and Lotte Nedergaard and Lene Lundvall and Claus H{\o}gdall",
note = "Keywords: Adenocarcinoma; Adult; Aged; Aged, 80 and over; CA-125 Antigen; Female; Gynecologic Surgical Procedures; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Prognosis; Proteomics; ROC Curve; Sensitivity and Specificity; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Treatment Outcome; Tumor Markers, Biological",
year = "2009",
month = dec,
day = "1",
doi = "10.1111/IGC.0b013e3181a840f5",
language = "English",
volume = "19",
pages = "1535--8",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams & Wilkins, Ltd.",
number = "9",

}

RIS

TY - JOUR

T1 - A proteomics panel for predicting optimal primary cytoreduction in stage III/IV ovarian cancer

AU - Risum, Signe

AU - Høgdall, Estrid

AU - Engelholm, Svend A

AU - Fung, Eric

AU - Lomas, Lee

AU - Yip, Christine

AU - Petri, Anette L

AU - Nedergaard, Lotte

AU - Lundvall, Lene

AU - Høgdall, Claus

AU - Risum, Signe

AU - Høgdall, Estrid

AU - Engelholm, Svend A

AU - Fung, Eric

AU - Lomas, Lee

AU - Yip, Christine

AU - Petri, Anette L

AU - Nedergaard, Lotte

AU - Lundvall, Lene

AU - Høgdall, Claus

N1 - Keywords: Adenocarcinoma; Adult; Aged; Aged, 80 and over; CA-125 Antigen; Female; Gynecologic Surgical Procedures; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Prognosis; Proteomics; ROC Curve; Sensitivity and Specificity; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Treatment Outcome; Tumor Markers, Biological

PY - 2009/12/1

Y1 - 2009/12/1

N2 - The objective of this prospective study was to evaluate CA-125 and a 7-marker panel as predictors of incomplete primary cytoreduction in patients with stage III/IV ovarian cancer (OC). From September 2004 to January 2008, serum from 201 patients referred to surgery for a pelvic tumor was analyzed for CA-125. In addition, serum was analyzed for 7 biomarkers using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. These biomarkers were combined into a single-valued ovarian-cancer-risk index (OvaRI). CA-125 and OvaRI were evaluated as predictors of cytoreduction in 75 stage III/IV patients using receiver operating characteristic curves. Complete primary cytoreduction (no macroscopic residual disease) was achieved in 31% (23/75) of the patients. The area under the receiver operating characteristic curve was 0.66 for CA-125 and 0.75 for OvaRI. The sensitivity and specificity of CA-125 for predicting incomplete cytoreduction were 71% (37/52) and 57% (13/23), respectively (P = 0.04). The sensitivity and specificity of OvaRI for predicting incomplete cytoreduction were 73% (38/52) and 70% (16/23), respectively (P = 0.001). In conclusion, CA-125 and an index of 7 biomarkers were found to be predictors of cytoreduction. However, future studies of biomarkers are anticipated to promote early diagnosis and provide prognostic information to guide treatment of OC patients. In addition, new biomarkers might also play a role in predicting outcome from primary surgery in OC patients.

AB - The objective of this prospective study was to evaluate CA-125 and a 7-marker panel as predictors of incomplete primary cytoreduction in patients with stage III/IV ovarian cancer (OC). From September 2004 to January 2008, serum from 201 patients referred to surgery for a pelvic tumor was analyzed for CA-125. In addition, serum was analyzed for 7 biomarkers using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. These biomarkers were combined into a single-valued ovarian-cancer-risk index (OvaRI). CA-125 and OvaRI were evaluated as predictors of cytoreduction in 75 stage III/IV patients using receiver operating characteristic curves. Complete primary cytoreduction (no macroscopic residual disease) was achieved in 31% (23/75) of the patients. The area under the receiver operating characteristic curve was 0.66 for CA-125 and 0.75 for OvaRI. The sensitivity and specificity of CA-125 for predicting incomplete cytoreduction were 71% (37/52) and 57% (13/23), respectively (P = 0.04). The sensitivity and specificity of OvaRI for predicting incomplete cytoreduction were 73% (38/52) and 70% (16/23), respectively (P = 0.001). In conclusion, CA-125 and an index of 7 biomarkers were found to be predictors of cytoreduction. However, future studies of biomarkers are anticipated to promote early diagnosis and provide prognostic information to guide treatment of OC patients. In addition, new biomarkers might also play a role in predicting outcome from primary surgery in OC patients.

U2 - 10.1111/IGC.0b013e3181a840f5

DO - 10.1111/IGC.0b013e3181a840f5

M3 - Journal article

C2 - 19955932

VL - 19

SP - 1535

EP - 1538

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 9

ER -

ID: 20572738